Tris Pharma captures FDA nod for non-stimulant ADHD treatment Onyda XR

Stimulants are typically the go-to option for doctors prescribing treatments for attention-deficit hyperactivity disorder (ADHD). But some ADHD patients do not respond adequately to stimulants or have difficulty with their side effects.

Providing a new alternative is Tris Pharma, which has won FDA approval for Onyda XR (clonidine hydrochloride). The extended-release oral suspension becomes the first liquid non-stimulant medication for ADHD and the only non-stimulant with nighttime dosing in the indication.